Most Recent Articles about TAK
Takeda down 2% on underwhelming TAK-788 data https://seekingalpha.com/news/3464620-takeda-2-percent-underwhelming-takminus-788-data?source=feed_news_all May 16, 2019 - Investors appear unmoved with interim data from an open-label Phase 1/2 clinical trial evaluating Takeda's (TAK -2.4%) oral TKI inhibitor TAK-788 in non-small cell lung cancer (NSCLC) patients
What's in the Cards for Sunesis (SNSS) This Earnings Season? http://www.zacks.com/stock/news/406478/whats-in-the-cards-for-sunesis-snss-this-earnings-season?cid=CS-ZC-FT-406478 May 01, 2019 - Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark http://www.zacks.com/stock/news/404524/seattle-genetics-sgen-q1-loss-narrows-revenues-top-mark?cid=CS-ZC-FT-404524 Apr 26, 2019 - Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.

Related Companies

Name Exchange Price Mkt Cap
CTXS Citrix Systems, Inc. NASDAQ $110.7 $15.02B
SNPS Synopsys, Inc. NASDAQ $100.12 $14.88B
VEEV Veeva Systems Inc. NYSE $104.48 $15.1B
SHOP Shopify Inc. NYSE $153.63 $14.46B
ANSS ANSYS, Inc. NASDAQ $183.85 $15.5B
Sector: Technology > Industry: Computer Software: Prepackaged Software